BioCentury | Apr 10, 2019
Distillery Therapeutics

Antibody-drug conjugate targeting ALK could treat neuroblastoma

...ALK inhibitor, for NSCLC and have the compound in Phase II testing for solid tumors. Xcovery Holding Co. LLC...
BioCentury | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

...at Shire plc, which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired in January. Cancer company Xcovery Holding Co. LLC...
...Liang. Mao was VP and head of the Johnson & Johnson China Lung Cancer Center. Xcovery...
...Staff Acadia Pharmaceuticals Inc. Aerie Pharmaceuticals Inc. Artios Pharma Ltd. Audentes Therapeutics Inc. Global Health Innovative Technology (GHIT) Fund Surface Oncology Inc. Xcovery Holding Co. LLC American...
BioCentury | Aug 17, 2018
Finance

Location, location, biotech

...III compounds. Ensartinib (X-396), a candidate for NSCLC, was obtained in a 2014 deal with Xcovery Holding Co. LLC...
...Jihe Group Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tyrogenex Inc., Rockville, Md. Xcovery Holding Co. LLC...
BioCentury | Oct 24, 2017
Distillery Therapeutics

Infectious disease

...the Genentech Inc. unit of Roche market Alecensa alectinib, an ALK inhibitor, to treat NSCLC. Xcovery Holding Co. LLC...
BioCentury | Jul 28, 2017
Clinical News

NCI launching Pediatric MATCH trial

...AstraZeneca plc (LSE:AZN; NYSE:AZN); ensartinib (X-396), an inhibitor of anaplastic lymphoma kinase (ALK) , from Xcovery Holding Co. LLC...
...safety, pharmacokinetics and progression-free survival (PFS) Status: Phase II started Milestone: NA Chris Lieu ensartinib larotrectinib Lynparza selumetinib tazemetostat X-396 Zelboraf Epizyme Inc. Loxo Oncology Inc. Xcovery Holding Co. LLC Array...
BioCentury | Jul 24, 2017
Clinical News

NCI launching Pediatric MATCH trial

...kinase kinase 1 ( MAP2K1 ; MEK1) and MAP2K2 (MEK2); ensartinib ( X-396 ) from Xcovery Holding Co. LLC...
...screen 1,000 patients; each treatment arm will enroll at least 20 patients. Chris Lieu ensartinib larotrectinib Lynparza selumetinib tazemetostat X-396 Zelboraf Epizyme Inc. Loxo Oncology Inc. Xcovery Holding Co. LLC Array...
BioCentury | Apr 20, 2017
Finance

Zuckerberg’s research network

...and Co. (NYSE:LLY), Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Loxo Oncology Inc . (NASDAQ:LOXO) and Xcovery Holding Co. LLC...
BioCentury | Jan 12, 2017
Politics & Policy

NCI launches drug formulary

...of Roche (SIX:ROG; OTCQX:RHHBY), Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Loxo Oncology Inc. (NASDAQ:LOXO), and Xcovery Holding Co. LLC...
BioCentury | Jul 11, 2016
Clinical News

X-396: Phase III started

...prior chemotherapy regimen and no prior ALK inhibitor. Betta has Chinese rights to X-396 from Xcovery...
...a 2014 deal (see BioCentury, Nov. 3, 2014). Betta Pharmaceuticals Co. Ltd. , Hangzhou, China Xcovery Holding Co. LLC...
BioCentury | Apr 1, 2015
Company News

Management tracks

...is resigning. Michael Webb will replace Sheridan Snyder as president and CEO of cancer play Xcovery Holding Co. LLC...
...Tyrogenex Inc. (West Palm Beach, Fla.). Snyder, who co-founded both companies, will remain chairman at Xcovery...
Items per page:
1 - 10 of 21
BioCentury | Apr 10, 2019
Distillery Therapeutics

Antibody-drug conjugate targeting ALK could treat neuroblastoma

...ALK inhibitor, for NSCLC and have the compound in Phase II testing for solid tumors. Xcovery Holding Co. LLC...
BioCentury | Apr 1, 2019
Company News

Management tracks: AACR, Acadia, Aerie

...at Shire plc, which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) acquired in January. Cancer company Xcovery Holding Co. LLC...
...Liang. Mao was VP and head of the Johnson & Johnson China Lung Cancer Center. Xcovery...
...Staff Acadia Pharmaceuticals Inc. Aerie Pharmaceuticals Inc. Artios Pharma Ltd. Audentes Therapeutics Inc. Global Health Innovative Technology (GHIT) Fund Surface Oncology Inc. Xcovery Holding Co. LLC American...
BioCentury | Aug 17, 2018
Finance

Location, location, biotech

...III compounds. Ensartinib (X-396), a candidate for NSCLC, was obtained in a 2014 deal with Xcovery Holding Co. LLC...
...Jihe Group Co. Ltd., Hangzhou, China Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Tyrogenex Inc., Rockville, Md. Xcovery Holding Co. LLC...
BioCentury | Oct 24, 2017
Distillery Therapeutics

Infectious disease

...the Genentech Inc. unit of Roche market Alecensa alectinib, an ALK inhibitor, to treat NSCLC. Xcovery Holding Co. LLC...
BioCentury | Jul 28, 2017
Clinical News

NCI launching Pediatric MATCH trial

...AstraZeneca plc (LSE:AZN; NYSE:AZN); ensartinib (X-396), an inhibitor of anaplastic lymphoma kinase (ALK) , from Xcovery Holding Co. LLC...
...safety, pharmacokinetics and progression-free survival (PFS) Status: Phase II started Milestone: NA Chris Lieu ensartinib larotrectinib Lynparza selumetinib tazemetostat X-396 Zelboraf Epizyme Inc. Loxo Oncology Inc. Xcovery Holding Co. LLC Array...
BioCentury | Jul 24, 2017
Clinical News

NCI launching Pediatric MATCH trial

...kinase kinase 1 ( MAP2K1 ; MEK1) and MAP2K2 (MEK2); ensartinib ( X-396 ) from Xcovery Holding Co. LLC...
...screen 1,000 patients; each treatment arm will enroll at least 20 patients. Chris Lieu ensartinib larotrectinib Lynparza selumetinib tazemetostat X-396 Zelboraf Epizyme Inc. Loxo Oncology Inc. Xcovery Holding Co. LLC Array...
BioCentury | Apr 20, 2017
Finance

Zuckerberg’s research network

...and Co. (NYSE:LLY), Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Loxo Oncology Inc . (NASDAQ:LOXO) and Xcovery Holding Co. LLC...
BioCentury | Jan 12, 2017
Politics & Policy

NCI launches drug formulary

...of Roche (SIX:ROG; OTCQX:RHHBY), Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Loxo Oncology Inc. (NASDAQ:LOXO), and Xcovery Holding Co. LLC...
BioCentury | Jul 11, 2016
Clinical News

X-396: Phase III started

...prior chemotherapy regimen and no prior ALK inhibitor. Betta has Chinese rights to X-396 from Xcovery...
...a 2014 deal (see BioCentury, Nov. 3, 2014). Betta Pharmaceuticals Co. Ltd. , Hangzhou, China Xcovery Holding Co. LLC...
BioCentury | Apr 1, 2015
Company News

Management tracks

...is resigning. Michael Webb will replace Sheridan Snyder as president and CEO of cancer play Xcovery Holding Co. LLC...
...Tyrogenex Inc. (West Palm Beach, Fla.). Snyder, who co-founded both companies, will remain chairman at Xcovery...
Items per page:
1 - 10 of 21